단장증후군 시장 예측 : 진단, 치료, 약제 클래스별, 유통 채널 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Short Bowel Syndrome Market is accounted for $2.9 billion in 2026 and is expected to reach $10.9 billion by 2034 growing at a CAGR of 17.9% during the forecast period. A part of the small or large intestine may physically disappear or cease to function, resulting in the complicated condition known as short bowel syndrome. As a result, malabsorption-the decreased absorption of nutrients such as lipids, carbohydrates (sugars), vitamins, minerals, trace elements, and fluids-occurs often in people with small bowel syndrome. Malnutrition, inadvertent weight loss, and other symptoms might result from the deficiency of vital vitamins and minerals.

According to the data published by WebMD LLC in 2021, the cost of parenteral support per person is around USD 65,000 to USD 320,000 annually.

Market Dynamics:

Driver:

Increased demand of intravenous supplementation of fluids

Patients with this disease are increasingly requiring intravenous fluid supplementation to maintain normal urine flow and hydration levels. Given that these individuals have difficulties, a number of prominent firms in the industry are attempting to address this need. Since the loss of the distal ileum results in malabsorption of magnesium, which causes hypomagnesemia, a number of firms are creating magnesium supplements to aid patients in getting enough water.

Restraint:

Dangerous side effects

The main obstacle facing the market is the adverse effects of medications used to treat short bowel syndrome. The most typical side effects of Revestive or Gattex on health include headaches, nausea, vomiting, colds, and flu. Furthermore, it has been shown that these medications may result in other health issues such colon polyps, gallbladder inflammation, pancreatic obstruction, aberrant cell development that may result in cancer, and intestinal blockage.

Opportunity:

Prevalence of short bowel syndrome

Short bowel syndrome has become more common in recent years. The number of patients receiving complete parenteral nutrition is growing, which has fueled market expansion. The estimated incidence of short bowel syndrome is four cases per million, although actual incidence is closer to three cases per million. Given the amount of patients receiving parenteral nourishment, the disease's precise prevalence is predicted, despite the lack of clarity in this regard.

Threat:

High treatment cost

The most popular therapy for treating this illness is parenteral feeding, which comes with a high expense for the entire course of care. Both in-hospital and at-home environments can perform this treatment. On the other hand, compared to patients getting parenteral nourishment in hospitals, the cost of care for those receiving it at home is lower. Furthermore, the prohibitive yearly expense of the medications used to treat this illness further restricts their commercial acceptance.

Covid-19 Impact:

Manufacturers in the short bowel syndrome market are expanding their income prospects as a result of the results, since individuals with COVID-19 have reported experiencing gastrointestinal issues. On the other hand, long-term parenteral feeding or an organ transplant are necessary for the SBS therapy. Thus, businesses and academics ought to work together to further the field of autologous tissue engineering research, which enables patients to be treated with their own cells or tissues. Businesses are increasing their production of growth hormones, hypomotility drugs and anti-secretin medicines.

The glutamine segment is expected to be the largest during the forecast period

The glutamine segment is expected to be the largest during the forecast period. An amino acid called glutamine is the main energy source for the intestinal lining cells. It supports the operation of the gut barrier, aids in preserving the integrity of the intestinal mucosa, and may even lessen intestinal permeability. By encouraging the repair of the intestinal tissues and shortening the recovery period following intestinal surgery, it may facilitate recuperation.

The medications segment is expected to have the highest CAGR during the forecast period

The medications segment is expected to have the highest CAGR during the forecast period. Drugs can aid in the relief of symptoms including bloating, diarrhea, stomach discomfort, and nutritional deficits that are frequently linked to this illness. Certain drugs can make up for the decreased functional surface area of the gut by improving the absorption of nutrients and electrolytes. This aids in the prevention of malnutrition and its consequences.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the increased sedentary lifestyle, increased healthcare infrastructure, and rising funding from the government on the research of Crohn's disease, among others. The use of short bowel syndrome has expanded significantly in recent years due to the development in sedentary lifestyles, which have left people with less time to focus on eating wholesome foods and more junk food. As a result, the market for intestinal diseases has continued to grow.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The market is growing in this area due to the direct presence of large companies, significant R&D investments in the development of novel medications, and an increasing emphasis on clinical trials for GLP-2-based therapies. The primary reasons propelling the market expansion are the notable increase in short bowel syndrome cases, especially in emerging nations, rapid urbanization, and rising government spending on healthcare infrastructure.

Key players in the market

Some of the key players in Short Bowel Syndrome market include VectivBio AG, Takeda Pharmaceutical Company Limited, Nutrinia, Merck KGaA, Ardelyx, OxThera Inc, Zealand Pharma, Nestle Health Science, Hanmi Pharm.Co., Ltd, Sancilio&Company Inc, Meters Biopharma and OPKO Health, Inc.

Key Developments:

In September 2022, Zealand Pharma A/S announced positive results from a phase 3 trial of Glepaglutide for treatment of short bowel syndrome. Glepaglutide is the potential best-in-class long-acting GLP-2 analog. The candidate has distinct advantages over Teduglutide, including once-weekly dosing and a longer half-life.

In March 2022, VectivBio AG announced a licensing agreement with Asahi Kasei Pharma Corporation to commercialize and develop apraglutide in Japan, which is used to treat SBS.

Diagnoses Covered:

• Blood Tests
• Imaging Procedures
• Physical Exam
• Other Diagnoses

Treatments Covered:

• Medications
• Surgery
• Nutritional Therapy
• Transplant
• Other Treatments

Drug Classes Covered:

• Glutamine
• GLP-2
• Growth Hormone
• Zorbtive
• Proton Pump Inhibitors
• Histamine Blockers
• Glucagon
• Anti-Diarrheals
• Other Drug Classes

Distribution Channels Covered:

• Medications
• Surgery
• Nutritional Therapy
• Transplant
• Other Treatments

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Short Bowel Syndrome Market, By Drug Class

• 5.1 Introduction
• 5.2 Glutamine
• 5.3 GLP-2
• 5.4 Growth Hormone
• 5.5 Zorbtive
• 5.6 Proton Pump Inhibitors
• 5.7 Histamine Blockers
• 5.8 Glucagon
• 5.9 Anti-Diarrheals
• 5.10 Other Drug Classes

6 Global Short Bowel Syndrome Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Retail Pharmacies
• 6.3 Hospital Pharmacies
• 6.4 Online Sales

7 Global Short Bowel Syndrome Market, By Diagnosis

• 7.1 Introduction
• 7.2 Blood Tests
• 7.3 Imaging Procedures
  • 7.3.1 Magnetic Resonance Imaging (MRI)
  • 7.3.2 X-ray with a Contrast Material
  • 7.3.2 Computerized Tomography (CT) Scan
• 7.4 Physical Exam
• 7.5 Other Diagnoses

8 Global Short Bowel Syndrome Market, By Treatment

• 8.1 Introduction
• 8.2 Medications
• 8.3 Surgery
• 8.4 Nutritional Therapy
  • 8.4.1 Enteral Nutrition
  • 8.4.2 Parenteral Nutrition
• 8.5 Transplant
• 8.6 Other Treatments

9 Global Short Bowel Syndrome Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 VectivBio AG
• 11.2 Takeda Pharmaceutical Company Limited
• 11.3 Nutrinia
• 11.4 Merck KGaA
• 11.5 Ardelyx
• 11.6 OxThera Inc
• 11.7 Zealand Pharma
• 11.8 Nestle Health Science
• 11.9 Hanmi Pharm.Co., Ltd
• 11.10 Sancilio&Company Inc
• 11.11 Meters Biopharma
• 11.12 OPKO Health, Inc.